<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="196470">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533442</url>
  </required_header>
  <id_info>
    <org_study_id>20000176</org_study_id>
    <nct_id>NCT00533442</nct_id>
  </id_info>
  <brief_title>Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients</brief_title>
  <official_title>Tacrolimus and Mycophenolate Mofetil vs Tacrolimus and Sirolimus in SPK, Pancreas After Kidney or Pancreas Transplant Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine which immunosuppressive agent, rapamycin or
      mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal
      failure, who presented for a kidney-pancreas transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, prospective single center study evaluating the two drugs above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from acute rejection; kidney or pancreas transplant loss, and death at one year after transplant.</measure>
    <time_frame>one to seven years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 month safety and efficacy assessments including side effects and overall kidney and pancreas transplant function.</measure>
    <time_frame>one to seven years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>TAC and MMF and Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of kidney-pancreas recipients was randomized to receive mycophenolate mofetil and tacrolimus after transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tacrolimus and rapamune</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm received Sirolimus, after kidney-pancreas transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.</description>
    <arm_group_label>tacrolimus and rapamune</arm_group_label>
    <other_name>RapamuneÂ® (sirolimus)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus and mycophenolate mofetil</intervention_name>
    <description>MMF 1 gm BID beginning 1st day postoperative day</description>
    <arm_group_label>TAC and MMF and Steroid</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamune and Tacrolimus</intervention_name>
    <description>Sirolimus 2 mg/day beginning 1st postoperative day (trough target levels:
10-15ng/ml)</description>
    <arm_group_label>tacrolimus and rapamune</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.</description>
    <arm_group_label>tacrolimus and rapamune</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with Type 1 diabetes and end stage renal disease.

          -  Women of childbearing potential must have had a negative pregnancy test (serum or
             urine).

          -  Patient agrees to participate in the study and sign an informed consent.

          -  Patient has no known contraindication to the administration of rapamycin or
             mycophenolate mofetil.

          -  Patient has no history of hypersensitivity to rapamycin or mycophenolate mofetil.

        Exclusion Criteria:

          -  Patient has history of a malignancy within two years, with the exception of
             adequately treated localized squamous or basal cell carcinoma of the skin without
             evidence of recurrence.

          -  Patient is currently abusing drugs or alcohol.

          -  Patient is known or suspected to have an active infection or be seropositive for
             hepatitis B surface antigen (HBsAg), hepatitis C (HCV) or human immunodeficiency
             virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George W Burke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Burke GW 3rd, Ciancio G, Figueiro J, Olson L, Gomez C, Rosen A, Suzart K, Miller J. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. Transplant Proc. 2002 Aug;34(5):1918-9.</citation>
    <PMID>12176628</PMID>
  </results_reference>
  <results_reference>
    <citation>Burke G 3rd, Ciancio G, Figueiro J, Olson L, Gomez C, Rosen A, Suzart K, Miller J. Can acute rejection be prevented in SPK transplantation? Transplant Proc. 2002 Aug;34(5):1913-4.</citation>
    <PMID>12176626</PMID>
  </results_reference>
  <results_reference>
    <citation>Burke GW 3rd, Ciancio G, Figueiro J, Buigas R, Olson L, Roth D, Kupin W, Miller J. Hypercoagulable state associated with kidney-pancreas transplantation. Thromboelastogram-directed anti-coagulation and implications for future therapy. Clin Transplant. 2004 Aug;18(4):423-8.</citation>
    <PMID>15233820</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 2, 2016</lastchanged_date>
  <firstreceived_date>September 19, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>George W. Burke</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Rapamycin</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>kidney-pancreas transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
